Share
   
Title
Code
Session Type
Venue
Date Time
Chair:
Organizer:

HIV/AIDS remains a major global health challenge with 37 million people living with HIV, and over 2 million new infections every year. New biomedical prevention strategies (such as PrEP and PEP), can make a substantial contributions to halting HIV, but may be difficult to sustain in the long-term. Research is ongoing into non-ARV based interventions, and a vaccine could still present the most effective public health tool in combating HIV/AIDS. As one of the new initiatives launched by the European Commission, the European HIV Vaccine Alliance (EHVA) aims to develop improved vaccine candidates and tools predictive of immunogenicity and of correlates of protection. This EHVA-hosted satellite symposium will provide an overview of the latest developments in HIV prevention broadly, and prophylactic and therapeutic HIV vaccines in particular, as well as introduce key areas of work for EHVA.

12:30
Welcome and introduction
Yves Levy, INSERM, France
12:45
The EU’s research strategy and its impact on the HIV vaccine landscape
Alessandra Martini, European Commission DG Research and Innovation, Belgium
12:55
A review of HIV prevention: advances, challenges and new approaches
Glenda Gray, South African Medical Research Council, South Africa
13:15
HIV envelope proteins: where we are and where we are going
Winfried Weissenhorn, Institute for Structural Biology (IBS), France
13:25
The role of non-neutralising antibodies in preventing HIV infection
Susan Barnett, Bill & Melinda Gates Foundation, United States
13:35
Progress in achieving a functional cure and identifying virological and immunological markers
Giuseppe Pantaleo, Division of Immunology and Allergy, Lausanne University Hospital (CHUV), Switzerland
13:45
PANEL DISCUSSION